3 results about "Streptococcus sobrinus" patented technology

The invention relates to the technical field of biological medicine, and particularly discloses application of Xinjiang pomegranate rind ellagic acid in caries prevention, in-vivo and in-vitro experiments prove that the ellagic acid can effectively inhibit floating growth and biofilm formation of streptococcus mutans, streptococcus sobrinus and streptococcus sanguis, MICs of the ellagic acid are 4 mmol / L, 2 mmol / L and 1 mmol / L respectively, and MBICs of the ellagic acid are 8 mmol / L, 4 mmol / L and 1 mmol / L respectively; meanwhile, the ellagic acid can obviously inhibit the acid production capacity of the cariogenic bacteria, the generation of water-insoluble exopolysaccharides and the adhesion to hydroxyapatite; in a rat caries model, by locally applying 1-8 mmol / L ellagic acid, the number of streptococcus in the oral cavity can be reduced in a dose-dependent manner, the caries damage degree of smooth surfaces of molar teeth and fossa and fissure can be relieved, the effect of the ellagic acid is equivalent to that of positive control drugs chlorhexidine and sodium fluoride under the high dose (8 mmol / L), and the ellagic acid shows good biological safety. Therefore, ellagic acid can be used for preparing safe and effective anti-caries drugs or oral care products.

The application belongs to the technical field of biological medicine, and particularly relates to an antimicrobial peptide and application thereof in preparation of products for preventing and / or treating oral diseases. The amino acid sequence of the antimicrobial peptide Perceptide-302 is shown as SEQ ID NO. 1. Experimental results of the application show that the polypeptide can effectively inhibit and kill oral pathogenic bacteria at a low concentration, the minimum inhibitory concentration (MIC) of the polypeptide on six kinds of bacteria, including Streptococcus mutans, Streptococcus sobrinus, Streptococcus sanguis, Streptococcus gordonii, Lactobacillus casei and Lactobacillus acidophilus, is 2.5 μg / mL-5 μg / mL, the minimum bactericidal concentration (MBC) is 5 μg / mL-10 μg / mL, and mechanism research is carried out on the most important clinical Streptococcus mutans. The application provides a new active ingredient and technical approach for developing a new type, efficient and safe oral disease prevention and treatment drug and product.

The invention belongs to the technical field of lactobacillus paracasei, and particularly relates to a lactobacillus paracasei LPa-6 strain and application thereof in atopic dermatitis. The lactobacillus paracasei LPa-6 strain not only has the performance of targeted inhibition of Enterobacter cloacae, Streptococcus sobrinus and Aloscardovia omnicola, but also can be used for increasing the concentration of anti-inflammatory factors, regulating Th1 / Th2 imbalance, increasing the abundance of effective microbial communities in intestinal tracts, and effectively relieving and improving the symptoms of atopic dermatitis, and can be used for preventing and treating enterobacter cloacae, Streptococcus sobrinus and Aloscardovia omnicola, and preventing and treating enterobacter cloacae, Streptococcus sobrinus and Aloscardovia omnicola.